文献速递间质性肺疾病

尼达尼布与吡非尼酮在IPF患者中无相关药代动力学相互作用

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.
PubMed 文献 · Eur Respir J · 2019-01-10

这项开放标签、两组试验在IPF患者中研究尼达尼布与吡非尼酮的药代动力学相互作用。组1(n=20)先单用尼达尼布150mg,再用吡非尼酮滴定至801mg每日三次3周后再次单用尼达尼布;组2(n=17)继续吡非尼酮801mg每日三次7天后联合尼达尼布150mg每日两次7天。两药暴露的几何均值比90%CI均包含100%,提示无相关药代动力学相互作用,两药耐受良好。

要点

  • 尼达尼布与吡非尼酮联用时暴露的90%CI均包含100%,无相关药代动力学相互作用
  • 组1中尼达尼布AUC与Cmax的几何均值比分别为88.6%和80.6%
  • 组2中吡非尼酮AUC与Cmax的几何均值比分别为97.2%和99.5%

核心结论

  • 在IPF患者中联合使用尼达尼布与吡非尼酮不存在相关的药代动力学药物相互作用。

研究设计与样本

  • 开放标签、两组试验,组1为筛查时未接受抗纤维化治疗者(n=20),组2为筛查时正在接受吡非尼酮治疗者(n=17)。
  • 组1先单次尼达尼布150mg,随后吡非尼酮滴定至801mg每日三次用3周,第23天再单次尼达尼布150mg。
  • 组2继续吡非尼酮801mg每日三次7天,再联合尼达尼布150mg每日两次7天,第16天给予两药单次剂量。

主要发现

  • 组1中尼达尼布AUC与Cmax的几何均值比(联用/单用吡非尼酮)分别为88.6%和80.6%。
  • 组2中吡非尼酮AUC与Cmax的几何均值比(联用/单用尼达尼布)分别为97.2%和99.5%。
  • 所有参数的90%置信区间均包含100%,提示单用与联用暴露相似。
  • 两种治疗均耐受良好。

临床怎么用

  • IPF患者联合使用尼达尼布与吡非尼酮时,无需基于药代动力学相互作用调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nintedanib and pirfenidone are approved treatments for idiopathic pulmonary fibrosis (IPF). This open-label, two-group trial investigated the pharmacokinetic drug-drug interaction between these two drugs in patients with IPF.Subjects not treated with antifibrotics at screening (group 1, n=20) received a single nintedanib dose (150 mg) followed by pirfenidone (titrated to 801 mg thrice daily) for 3 weeks, with a further single nintedanib dose (150 mg) on the last day (day 23). Subjects treated with pirfenidone at screening (group 2, n=17) continued to receive pirfenidone alone (801 mg thrice daily) for 7 days, then co-administered with nintedanib (150 mg twice daily) for a further 7 days, before single doses of both treatments on day 16.In group 1, adjusted geometric mean (gMean) ratios (with/without pirfenidone) were 88.6% and 80.6% for nintedanib area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax), respectively. In group 2, gMean ratios (with/without nintedanib) were 97.2% and 99.5% for pirfenidone AUC and Cmax, respectively. For all parameters, the 90% confidence intervals included 100%, suggesting similar exposure for administration alone and when co-administered. Both treatments were well tolerated.These data indicate there is no relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone when co-administered in IPF patients.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Richeldi L, Fletcher S, Adamali H, et al. No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone. Eur Respir J. 2019. PMID: 30442716. doi:10.1183/13993003.01060-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。